Skip to main content
. Author manuscript; available in PMC: 2017 Jun 21.
Published in final edited form as: Circulation. 2016 Jun 21;133(25):2618–2625. doi: 10.1161/CIRCULATIONAHA.115.019214

Figure 3. Disease in a dish specific to individual patients.

Figure 3

Even if most patients do not receive cellular therapies, regenerative biology will provide new testing platforms for therapy development. Generation of laboratory cells and tissues from specific patients provides the true genetic background of the disease. This approach is currently challenged by cost, time and reproducibility, but advances over the next decade will make this a routine approach for many diseases.